Free tool
FAERS Monitor: Fyarro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213312 or its brand name (Fyarro, Sirolimus). Reports on generic versions are filed under their own applications.
Reports
13,519
Serious
11,687
86% of reports
Hospitalization
4,682
Death reported
2,180
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,076
- drug ineffective1,140
- product use in unapproved indication786
- pyrexia533
- diarrhoea529
- pneumonia500
- drug interaction450
- acute kidney injury444
- thrombotic microangiopathy386
- transplant rejection384
- cytomegalovirus infection355
- condition aggravated318
- nausea318
- toxicity to various agents316
- death315
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 53 |
| 2006 | 51 |
| 2007 | 232 |
| 2008 | 194 |
| 2009 | 294 |
| 2010 | 152 |
| 2011 | 253 |
| 2012 | 231 |
| 2013 | 204 |
| 2014 | 239 |
| 2015 | 315 |
| 2016 | 425 |
| 2017 | 598 |
| 2018 | 845 |
| 2019 | 990 |
| 2020 | 1,021 |
| 2021 | 1,054 |
| 2022 | 1,240 |
| 2023 | 1,139 |
| 2024 | 1,444 |
| 2025 | 1,502 |
| 2026 | 1,002 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,640 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| transplant rejectionSignal | 384 | 78.2 | 70.7 | 27,819 |
| thrombotic microangiopathySignal | 386 | 64.1 | 58.0 | 22,986 |
| cytomegalovirus infectionSignal | 355 | 33.9 | 30.6 | 11,081 |
| product use in unapproved indicationSignal | 786 | 4.9 | 4.6 | 2,493 |
| acute kidney injurySignal | 444 | 4.5 | 4.1 | 1,221 |
| drug interactionSignal | 450 | 4.4 | 4.0 | 1,194 |
| off label useSignal | 2,076 | 3.7 | 3.6 | 4,245 |
| toxicity to various agentsSignal | 316 | 2.9 | 2.6 | 399 |
| pneumoniaSignal | 500 | 2.4 | 2.2 | 415 |
| pyrexiaSignal | 533 | 2.4 | 2.2 | 440 |
| condition aggravated | 318 | 1.6 | 1.5 | 77 |
| drug ineffective | 1,140 | 1.3 | 1.3 | 108 |
| diarrhoea | 529 | 1.3 | 1.2 | 32 |
| nausea | 318 | 0.6 | 0.6 | 74 |
| death | 315 | 0.6 | 0.5 | 107 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.